Press Releases

NEW YORK, April 29, 2024 /PRNewswire/ -- This press release provides shareholders of Cohen & Steers Closed-End Opportunity Fund, Inc. (NYSE: FOF) (the "Fund") with information regarding the sources of the distribution to be paid on April 30, 2024 and cumulative distributions paid fiscal year-to-date.

In December 2021, the Fund implemented a managed distribution policy in accordance with exemptive relief issued by the Securities and Exchange Commission. The managed... (continue reading...)

IRVINE, Calif., April 29, 2024 /PRNewswire/ -- BTC POWER, a leading innovator in electric vehicle (EV) charging solutions, is excited to announce its participation in the upcoming Advanced Clean Transportation (ACT) Expo, scheduled to take place in Las Vegas, Nevada, May 20-23rd, 2024. At the expo, BTC POWER will proudly introduce its latest innovation, the Gen 4 Fleet Dispenser, designed to revolutionize EV charging for fleet operators.

... (continue reading...)

PHOENIX, April 29, 2024 /PRNewswire/ -- PetSmart LLC (the "Company" or "PetSmart") will hold a conference call and webcast to review its results for the fourth quarter and fiscal year 2023 on Wednesday, May 1, 2024 at 4 p.m. ET., and the Company's fiscal year 2023 results will be made available on its secure website. The call and results will be made available to lenders under the Company's credit facilities, holders of the Company's 4.75% senior first lien notes due... (continue reading...)

TORONTO and TAMPA, Fla., April 29, 2024 (GLOBE NEWSWIRE) -- Voxtur Analytics Corp. (TSXV: VXTR; OTCQB: VXTRF) ("Voxtur" or the "Company"), a North American technology company creating a more transparent and accessible real estate lending ecosystem, today announced its financial results for the three months and year ended December 31, 2023. The Company's Audited Consolidated Financial Statements for year ended December 31, 2023, and the related Management's Discussion... (continue reading...)

SALT LAKE CITY, April 29, 2024 /PRNewswire/ -- A final FDA rule regulating laboratory-developed tests (LDTs) as medical devices does not address serious concerns raised by ARUP Laboratories and the clinical laboratory community, and the company's stance on the rule has not changed, CEO Andy Theurer said today. ARUP believes the FDA does not have statutory authority over LDTs and maintains that the rule will limit access to essential testing services, stifle... (continue reading...)